RNAZ - TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium | Benzinga
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year's San Antonio Breast Cancer Symposium scheduled to take place December 5-9 in San Antonio, TX.
The abstract, "Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins" will be presented as a poster. The poster will describe the clinical development of TTX-MC138, a therapeutic miR-10b inhibitor, delivered to metastatic tumor cells that has elicited complete responses and life-long disease remissions in preclinical models of adenocarcinoma. The poster details the IND-enabling work in support of the Phase 0 trial with Cu64-labeled TTX-MC138 as well as initial results from the trial. The trial involves injection of a microdose of Cu64-labeled TTX-MC138 into stage IV breast cancer patients, followed by positron emission tomography-magnetic resonance imaging (PET-MRI). The trial seeks to determine the pharmacokinetics of TTX-MC138 and its uptake in metastatic lesions. Studies that will be presented in support of the Phase 0 trial include dosimetry/pharmacokinetic (PK) and tissue distribution, as well as metabolite analysis in non-human primates. In addition, initial clinical data on drug candidate PK and accumulation in clinical metastases, as well as drug candidate stability, will be discussed.
TransCode believes that the impact of this work is three-fold. First, TransCode believes these data show that TTX-MC138 has the potential to accumulate in human metastases as occurred in preclinical animal studies. TransCode believes this supports further clinical development of the therapeutic candidate because it shows that delivery of the therapeutic candidate to metastases is feasible. Second, the Phase 0 trial has the potential to reveal the pharmacokinetic behavior of TTX-MC138 which could inform dosing ...